ArticleJournal, genetic engineering & biotechnology2025
Quercetin-liposomes effectively regulated the Nrf2/Keap1 and NF-κB/P38 MAPK signaling pathways and protected the liver against paracetamol-induced damage.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quercetin as a Multifunctional Flavonol: Molecular Insights and Therapeutic Applications.Molecules (Basel, Switzerland) · 2026Review
- The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of hepatotoxicity has sharply increased worldwide in recent decades. Our study aimed to enhance quercetin's effectiveness against paracetamol (PCM)-induced hepatotoxicity using a quercetin liposome nano formulation. The quercetin liposome (QL) nano formula was fabricated by applying the thin-film hydration method. It was examined via dynamic light scattering, confirmed with a transmission electron microscope (TEM), and followed by assessments of drug-loading capacity, encapsulation efficiency (EE%), and Fourier transform infrared (FTIR) spectroscopy. The release features and cell cytotoxicity were also assessed. The in vivo parameters were completed. We effectively synthesized and characterized the quercetin liposome nanoformula with a 501.9 nm particle size and a -22.8 mV zeta potential. TEM imaging showed that quercetin liposomes were spherical. The EE% for the optimized formulation was 77.1 %. FTIR test confirmed the quercetin liposome spectra. Sustained release behavior of about 67.45 % of quercetin was released from liposomes by 24 h. The IC50 value was reduced from 71.32 µg/ml to 51.28 µg/ml for quercetin and quercetin-loaded liposomes. For the in vivo study, quercetin liposome improved all the altered biochemical markers, alleviating the levels of Malondialdehyde (MDA), Nitric oxide (NO), Superoxide dismutase (SOD), and Glutathione peroxidase (GPx), and upregulating Nuclear factor erythroid 2-related factor 2 (Nrf2) with a downregulation of Kelch-like ECH-associated protein 1 (Keap1), Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and p38 Mitogen-activated protein kinase (P38 MAPK) gene expression that paralleled the histopathological amelioration. Our results suggested that the quercetin liposome nano formulation had potent hepatoprotective activity through ameliorating biochemical indicators, oxidative stress markers, upregulation of anti-apoptotic genes, and improvement in the histopathological index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.